Endothelial function trajectories during anthracycline chemotherapy by baseline cardiovascular risk: a prospective three-time point study

Aiganym Amanova, Zhenisgul Sh. Tlegenova, Saule K. Balmagambetova, Gulnara Kurmanalina, Iliada Talipova, Gulmira Sultanbekova, Kulparshan Kubenova, Mira Baspayeva, Saule Madinova, Z Bulekova

1 more author

B Zholdin

2026

Closed access Metadata (CSL-JSON)
DOI 10.1093/eurheartjsupp/suag097.108
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Abstract Background In patients receiving anthracycline therapy, a decline in FMD reflects the development of endothelial dysfunction and may represent an early vascular response preceding myocardial involvement. Nevertheless, whether early FMD changes can reliably predict subsequent asymptomatic left ventricular dysfunction remains an open question. Purpose To evaluate longitudinal changes in FMD according to baseline cardiovascular risk and to explore whether early FMD changes are associated with subsequent asymptomatic cancer-therapy-related cardiac dysfunction (CTRCD) during anthracycline therapy. Methods This prospective analysis included 71 women (mean age 55.4±11.2 years) receiving anthracycline-containing chemotherapy. Patients were stratified into a low-risk group (n=40) and a moderate-to-high-very high risk group (n=31)according to the HFA-ICOS risk assessment. Cardiovascular evolution, monitoring and definition of asymptomatic CTRCD followed the 2022 ESC cardio-oncology recommendations. FMD was measured at baseline (T0), after 4 cycles (T1), and after 8 cycles (T2) using a validated automated FMD analysis. Between-group difference and longitudinal changes in FMD were performed using appropriate non-parametric methods. The association between early FMD change and CTRCD was assessed using logistic regression with adjustment for baseline cardiovascular risk; an additional threshold analysis evaluated the upper quartile of early FMD decrease (≥0.70). Results Cumulative anthracycline dose was 225.0±44.5 mg/m² in the low-risk group and 209.1±45.1 mg/m² in the moderate-to-high-very high risk group. FMD values were consistently higher in the low-risk group than in the moderate-to-high-very high risk group at baseline (11.40% vs 7.80%; p<0.001), after 4 cycles (10.85% vs 7.10%; p<0.001), and after 8 cycles (10.60% vs 6.50%; p<0.001) (Figure 1). A significant decline in FMD over time was observed in both risk groups (p < 0.001). Asymptomatic LV dysfunction after 8 cycles occurred in 19/71 patients (26.7%), with no significant difference between risk groups. Early FMD decline was not associated with the occurrence of asymptomatic CTRCD in univariable analysis OR 1.06(95% CI 0.85-1.32) or after adjustment for baseline cardiovascular risk OR 1.09(95% CI 0.86-1.37). The threshold analysis (Early FMD decrease ≥0.70) also showed no difference in outcome frequency (p=0.699). Conclusions During anthracycline chemotherapy, FMD trajectories differ according to baseline cardiovascular risk, with consistently lower FMD values in patients with moderate-to-high risk. In this cohort, early decline in FMD was not associated with subsequent asymptomatic LV dysfunction, suggesting that endothelial dysfunction, while an early vascular response to chemotherapy, may not be sufficient as a stand-alone predictor of CTRCD.Figure 1